Our deals: eTheRNA immunotherapies closes series B investment round

Supporting the € 34M Series B round of eTheRNA immunotherapies and the outline of a new strategic partnership

eTheRNA immunotherapies NV, a clinical-stage biotech developing mRNA therapeutics for cancer and infectious diseases, announced that it has successfully raised € 34M in a series B equity financing round.

The series B was joined by new investors Grand Decade, a BVI subsidiary owned by China Grand Pharmaceutical and Healthcare Holdings Ltd (‘GP(HK)’; HKSE Stock code 00512), BNP Paribas Fortis Private Equity (Belgium), Yijing Capital (China) and Novalis LifeSciences LLC (USA).

GP(HK) and eTheRNA have also agreed outline terms for a possible exclusive strategic partnership for mRNA manufacturing, independent research and development, production, and commercialization in Greater China.

All existing investors – LSP (the Netherlands), PMV (Belgium), Boehringer Ingelheim Venture Fund (Germany), Fund+ (Belgium) and Omega Funds (USA) – participated in the round.

Proceeds of the financing will be used to further the clinical development and commercialization of its proprietary mRNA technology platforms and a broad range of therapeutic products in cancer and infectious disease indications including a cross-strain vaccine against SARS-CoV-2.

How Agio Capital & Business Solutions helped

Agio contributed to eTheRNA’s Series B financing by supporting the capital contribution from Chinese investors and introducing the company to possible corporate partners and supported eTheRNA in strategic partnership discussions with Grand Pharmaceutical and Healthcare Holdings.

The addition of the Chinese investors to the syndicate broadens the investor base and provides access to the Greater China market.

For more information read the full press release.

More on subject(s)   Follow us at LinkedIn

Stay up to date